Abstract
Hyaluronan receptors (CD44, RHAMM) are over-expressed in a wide variety of cancers including bladder and ovarian tumors. Based on this rationale, a hyaluronic acid paclitaxel conjugate, ONCOFID™-P, was developed for the treatment of refractory bladder cancer and peritoneal carcinosis. ONCOFID™-P has demonstrated improved in vitro and in vivo efficacy in hyaluronan receptor-positive tumor models and a favorable toxicity profile in rodents. It has been investigated in 15 patients with refractory bladder cancer by intravesical instillation, showing promising antitumor efficacy with 60 % of treated patients achieving a complete response. As a consequence, phase II studies with ONCOFID™-P are ongoing in six European countries. In addition, phase I studies have been initiated investigating the maximum tolerated dose (MTD) and the safety profile of ONCOFID™-P following IP infusion in patients affected by intraperitoneal carcinosis in ovarian, breast, stomach, bladder and colon cancer.
Keywords: Hyaluronic acid, paclitaxel, anticancer, conjugate, bladder cancer, peritoneal carcinosis, colon cancer, antitumor, polysaccharide, drug conjugate
Current Bioactive Compounds
Title: ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis
Volume: 7 Issue: 1
Author(s): Monica Campisi and Davide Renier
Affiliation:
Keywords: Hyaluronic acid, paclitaxel, anticancer, conjugate, bladder cancer, peritoneal carcinosis, colon cancer, antitumor, polysaccharide, drug conjugate
Abstract: Hyaluronan receptors (CD44, RHAMM) are over-expressed in a wide variety of cancers including bladder and ovarian tumors. Based on this rationale, a hyaluronic acid paclitaxel conjugate, ONCOFID™-P, was developed for the treatment of refractory bladder cancer and peritoneal carcinosis. ONCOFID™-P has demonstrated improved in vitro and in vivo efficacy in hyaluronan receptor-positive tumor models and a favorable toxicity profile in rodents. It has been investigated in 15 patients with refractory bladder cancer by intravesical instillation, showing promising antitumor efficacy with 60 % of treated patients achieving a complete response. As a consequence, phase II studies with ONCOFID™-P are ongoing in six European countries. In addition, phase I studies have been initiated investigating the maximum tolerated dose (MTD) and the safety profile of ONCOFID™-P following IP infusion in patients affected by intraperitoneal carcinosis in ovarian, breast, stomach, bladder and colon cancer.
Export Options
About this article
Cite this article as:
Campisi Monica and Renier Davide, ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis, Current Bioactive Compounds 2011; 7 (1) . https://dx.doi.org/10.2174/157340711795163848
DOI https://dx.doi.org/10.2174/157340711795163848 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer
Current Medicinal Chemistry DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Epigenetic Variation and Customising Nutritional Intervention
Current Pharmacogenomics and Personalized Medicine Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Application of Bioactive Compounds and Drugs to Target Epigenetic Enzymes and Non-coding RNAs, Exploiting New Delivery Systems for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Free Radical Attack on Cholesterol: Oxysterols as Markers of Oxidative Stress and as Bioactive Molecules
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada
Current Drug Safety